A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis
Status:
Completed
Trial end date:
2019-11-05
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy and safety of rituximab compared with placebo in SSc
patients. This study consists of a 24-week, double-blind, placebo-controlled period followed
by a 24-week active drug treatment period.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Tokyo University
Collaborators:
Japan Agency for Medical Research and Development Zenyaku Kogyo Co., Ltd.